MA29310B1 - Composes inhibiteurs de raf et procedes - Google Patents
Composes inhibiteurs de raf et procedesInfo
- Publication number
- MA29310B1 MA29310B1 MA30151A MA30151A MA29310B1 MA 29310 B1 MA29310 B1 MA 29310B1 MA 30151 A MA30151 A MA 30151A MA 30151 A MA30151 A MA 30151A MA 29310 B1 MA29310 B1 MA 29310B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- inhibiting compounds
- raf
- raf inhibiting
- pyrazolyl compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS PYRAZOLYLE REPRÉSENTÉS PAR LA FORMULE IA QUI CONVIENNENT POUR INHIBER LA KINASE RAF ET POUR TRAITER DES TROUBLES INDUITS PAR CELLE-CI. CETTE INVENTION CONCERNE AUSSI DES PROCÉDÉS D'UTILISATION DES COMPOSÉS PYRAZOLYLE DE FAÇON À DIAGNOSTIQUER, PRÉVENIR OU TRAITER IN VITRO, IN SITU ET IN VIVO CES TROUBLES DANS DES CELLULES MAMMALIENNES OU DES ÉTATS PATHOLOGIQUES ASSOCIÉS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65005005P | 2005-02-04 | 2005-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29310B1 true MA29310B1 (fr) | 2008-03-03 |
Family
ID=36571626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30151A MA29310B1 (fr) | 2005-02-04 | 2007-08-17 | Composes inhibiteurs de raf et procedes |
Country Status (18)
Country | Link |
---|---|
US (2) | US7491829B2 (fr) |
EP (1) | EP1846391A2 (fr) |
JP (1) | JP2008530011A (fr) |
KR (1) | KR20070107104A (fr) |
CN (1) | CN101282960A (fr) |
AR (1) | AR053014A1 (fr) |
AU (1) | AU2006210626A1 (fr) |
BR (1) | BRPI0607346A2 (fr) |
CA (1) | CA2596973A1 (fr) |
CR (1) | CR9365A (fr) |
IL (1) | IL185024A0 (fr) |
MA (1) | MA29310B1 (fr) |
MX (1) | MX2007009405A (fr) |
NO (1) | NO20074473L (fr) |
RU (1) | RU2007133111A (fr) |
TW (1) | TW200639163A (fr) |
WO (1) | WO2006084015A2 (fr) |
ZA (1) | ZA200707289B (fr) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5153777B2 (ja) | 2006-10-02 | 2013-02-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼとしての化合物および組成物 |
US8188124B2 (en) | 2006-10-17 | 2012-05-29 | Stiefel Laboratories, Inc. | Talarazole metabolites |
EP2203453A1 (fr) * | 2007-09-20 | 2010-07-07 | Wyeth a Corporation of the State of Delaware | Pyrazolo[5,1-c] [1,2,4] triazines et leurs procédés de préparation et d'utilisation |
JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール[3,4−b]ピリジンRAF阻害剤 |
WO2009111260A1 (fr) * | 2008-02-29 | 2009-09-11 | Wyeth | Pyrazolo[1,5-a]pyrimidines substituées par phénylsulfonamide, leurs procédés de préparation et leurs utilisations |
WO2009111280A1 (fr) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Dérivés de n-(6-aminopyridin-3-yl)-3-(sulfonamido) benzamide comme inhibiteurs de b-raf pour le traitement du cancer |
AU2009222143A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2009108827A1 (fr) * | 2008-02-29 | 2009-09-03 | Wyeth | Pyrazolo[1,5-a]pyrimidines tricycliques condensées, procédés pour les préparer et leurs utilisations |
JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | RAF阻害化合物として使用されるイミダゾ[4,5−b]ピリジン誘導体 |
JP2009286773A (ja) * | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
EP2381777A4 (fr) * | 2008-12-12 | 2012-08-08 | Ariad Pharma Inc | Dérivés d'azaindole en tant qu'inhibiteurs de kinases |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
CA2772074A1 (fr) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Composes inhibiteurs de raf et leurs procedes d'utilisation |
CA2771895A1 (fr) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Composes inhibiteurs de raf kinases et leurs procedes d'utilisation |
JP2013503193A (ja) | 2009-08-28 | 2013-01-31 | ジェネンテック, インコーポレイテッド | Raf阻害剤化合物およびその使用方法 |
US20130018033A1 (en) | 2009-08-28 | 2013-01-17 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
CA2771893A1 (fr) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Composes inhibiteurs de raf et procedes d'utilisation de ceux-ci |
JP2013503194A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Rafキナーゼを阻害するための1H−ピラゾロ[3,4−B]ピリジン化合物 |
AU2010311321B2 (en) * | 2009-10-30 | 2014-11-27 | Prexton Therapeutics S.A. | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CA2786002C (fr) | 2009-12-31 | 2018-10-02 | Joaquin Pastor Fernandez | Composes tricycliques pour une utilisation comme inhibiteurs de la kinase |
US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
EP2423210A1 (fr) | 2010-08-25 | 2012-02-29 | Bayer CropScience AG | Dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides |
US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
BR112013010497B1 (pt) | 2010-10-27 | 2018-07-17 | Bayer Intellectual Property Gmbh | derivados de heteroaril - piperidina e - piperazina enquanto fungicidas, composição os compreendendo, bem como processo para a produção de composições para controle de fungos fitopatogênicos nocivos e método para controle de fungos fitopatogênicos nocivos |
US8937088B2 (en) | 2011-01-06 | 2015-01-20 | Astar Biotech Llc | Ureas for the treatment and prevention of cancer |
WO2012098387A1 (fr) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim |
KR101848116B1 (ko) | 2011-02-01 | 2018-04-11 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 살진균제로서의 헤테로아릴 피페리딘 및 헤테로아릴 피페라진 유도체 |
WO2012145503A1 (fr) | 2011-04-21 | 2012-10-26 | Novartis Ag | Combinaisons pharmaceutiques |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
ES2708669T3 (es) | 2011-08-01 | 2019-04-10 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK |
SG11201400724SA (en) | 2011-09-19 | 2014-04-28 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
EP2921495B1 (fr) | 2011-12-27 | 2018-03-28 | Bayer Intellectual Property GmbH | Dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides |
ES2588775T3 (es) * | 2011-12-31 | 2016-11-04 | Beigene, Ltd. | Compuestos tricíclicos fusionados como inhibidores de cinasa raf |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
CN110251512A (zh) | 2012-08-17 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法 |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
RU2015143437A (ru) | 2013-03-15 | 2017-04-27 | Дженентек, Инк. | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
JP6380862B2 (ja) | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物 |
CN108715615B (zh) | 2013-09-13 | 2020-11-27 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015164604A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
WO2015191986A1 (fr) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Méthodes de traitement et de prévention de la résistance du cancer aux médicaments |
US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
EP3169361B1 (fr) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions de traitement du cancer à l'aide d'antagonistes de liaison à l'axe pd-1 et d'inhibiteurs de mek |
NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
JP6909153B2 (ja) | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗pd−l1抗体 |
EP3236959A4 (fr) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10351559B2 (en) | 2015-04-15 | 2019-07-16 | Beigene, Ltd. | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
WO2016201370A1 (fr) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
CA2996978A1 (fr) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dependantes |
PL3377107T3 (pl) | 2015-11-19 | 2020-12-14 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu przy użyciu inhibitorów b-raf i inhibitorów immunologicznego punktu kontrolnego |
US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
FI3500299T3 (fi) | 2016-08-19 | 2024-02-14 | Beigene Switzerland Gmbh | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa |
IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
KR20230119252A (ko) * | 2016-12-23 | 2023-08-16 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를위한 화합물 및 방법 |
WO2018137681A1 (fr) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, préparation et utilisations associées |
EP3579872A1 (fr) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk |
EP3645569A4 (fr) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | Immunothérapie pour carcinome hépatocellulaire |
WO2019108795A1 (fr) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk |
WO2019133810A1 (fr) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations |
WO2021120890A1 (fr) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Dérivés pyrazolyle utiles en tant qu'agents anticancéreux |
TW202233607A (zh) * | 2020-10-30 | 2022-09-01 | 瑞士商諾華公司 | Kras g12c抑制劑化合物之新結晶形式 |
WO2023098439A1 (fr) * | 2021-11-30 | 2023-06-08 | 上海和誉生物医药科技有限公司 | Dérivé de pyrazole, son procédé de préparation et son utilisation en médecine |
WO2024022186A1 (fr) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | Composé méthylpyrazole, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation |
WO2024054591A1 (fr) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
JPH05125079A (ja) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | ピラゾロ[1,5−aピリミジン誘導体 |
EP0714898B1 (fr) | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | DERIVE DE PYRAZOLO [1,5-a]PYRIMIDINE |
US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
CA2206080A1 (fr) | 1995-09-28 | 1997-04-03 | Otsuka Pharmaceutical Factory, Inc. | Analgesiques |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
BR9809451A (pt) | 1997-05-22 | 2000-06-20 | Searle & Co | Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38. |
JP2000153671A (ja) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
WO2000064422A2 (fr) | 1999-04-27 | 2000-11-02 | Smithkline Beecham P.L.C. | Nouveau traitement |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
AU782878B2 (en) | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
SK14082001A3 (sk) | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
EP1263753B1 (fr) | 2000-03-06 | 2004-05-06 | SmithKline Beecham plc | Derives imidazole utilises comme inhibiteurs de la raf kinase |
MXPA03002449A (es) | 2000-09-21 | 2003-06-19 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de cinasa raf. |
CA2432148C (fr) | 2000-12-28 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Composes de derives tricycliques et heterocycliques et medicaments renfermant ces composes comme principe actif |
DE60223339T2 (de) | 2001-01-22 | 2008-08-28 | Sankyo Co., Ltd. | Durch bicyclische aminogruppen substituierte verbindungen |
AP2002002460A0 (en) | 2001-03-09 | 2002-06-30 | Pfizer Prod Inc | Novel benzimidazole anti-inflammatory compounds. |
ATE402164T1 (de) * | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
UA76461C2 (en) * | 2001-05-24 | 2006-08-15 | Lilly Co Eli | Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis |
WO2003011854A1 (fr) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de kinase derives du pyrazole et leurs utilisations |
DE60226154T2 (de) | 2001-08-03 | 2009-05-20 | Vertex Pharmaceuticals Inc., Cambridge | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
US20040010027A1 (en) | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
AU2002359714B2 (en) * | 2001-12-18 | 2006-12-21 | Merck Sharp & Dohme Corp. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
US7247734B2 (en) | 2001-12-21 | 2007-07-24 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
AU2003228770A1 (en) | 2002-05-10 | 2003-11-11 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
EP1539748A1 (fr) | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | Derives de c2-phenylpyridine-4-yl en tant qu'inhibiteurs d'alk5 |
GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
ATE343572T1 (de) * | 2002-08-09 | 2006-11-15 | Lilly Co Eli | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
US6967254B2 (en) | 2002-09-09 | 2005-11-22 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
ATE370139T1 (de) | 2002-09-17 | 2007-09-15 | Lilly Co Eli | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs |
CN1681501A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的吡唑衍生物 |
AU2003268155A1 (en) | 2002-09-19 | 2004-04-08 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
EP1567527A1 (fr) | 2002-11-27 | 2005-08-31 | Eli Lilly And Company | Derives pyrazolo condenses |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2006
- 2006-01-27 TW TW095103640A patent/TW200639163A/zh unknown
- 2006-02-02 BR BRPI0607346-8A patent/BRPI0607346A2/pt not_active IP Right Cessation
- 2006-02-02 RU RU2007133111/04A patent/RU2007133111A/ru not_active Application Discontinuation
- 2006-02-02 EP EP06734199A patent/EP1846391A2/fr not_active Withdrawn
- 2006-02-02 CA CA002596973A patent/CA2596973A1/fr not_active Abandoned
- 2006-02-02 KR KR1020077020119A patent/KR20070107104A/ko not_active Application Discontinuation
- 2006-02-02 CN CNA2006800109351A patent/CN101282960A/zh active Pending
- 2006-02-02 US US11/345,828 patent/US7491829B2/en not_active Expired - Fee Related
- 2006-02-02 JP JP2007554205A patent/JP2008530011A/ja active Pending
- 2006-02-02 AU AU2006210626A patent/AU2006210626A1/en not_active Abandoned
- 2006-02-02 MX MX2007009405A patent/MX2007009405A/es not_active Application Discontinuation
- 2006-02-02 WO PCT/US2006/003654 patent/WO2006084015A2/fr active Application Filing
- 2006-02-03 AR ARP060100401A patent/AR053014A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185024A patent/IL185024A0/en unknown
- 2007-08-17 MA MA30151A patent/MA29310B1/fr unknown
- 2007-08-28 ZA ZA200707289A patent/ZA200707289B/xx unknown
- 2007-09-03 NO NO20074473A patent/NO20074473L/no not_active Application Discontinuation
- 2007-09-04 CR CR9365A patent/CR9365A/es not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,412 patent/US20090176809A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20074473L (no) | 2007-10-31 |
EP1846391A2 (fr) | 2007-10-24 |
RU2007133111A (ru) | 2009-03-10 |
AR053014A1 (es) | 2007-04-18 |
CA2596973A1 (fr) | 2006-08-10 |
US20090176809A1 (en) | 2009-07-09 |
WO2006084015A3 (fr) | 2006-11-23 |
AU2006210626A1 (en) | 2006-08-10 |
BRPI0607346A2 (pt) | 2009-09-01 |
CN101282960A (zh) | 2008-10-08 |
US20060189627A1 (en) | 2006-08-24 |
IL185024A0 (en) | 2007-12-03 |
MX2007009405A (es) | 2007-09-25 |
JP2008530011A (ja) | 2008-08-07 |
ZA200707289B (en) | 2009-09-30 |
US7491829B2 (en) | 2009-02-17 |
CR9365A (es) | 2008-01-15 |
TW200639163A (en) | 2006-11-16 |
KR20070107104A (ko) | 2007-11-06 |
WO2006084015A2 (fr) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29310B1 (fr) | Composes inhibiteurs de raf et procedes | |
MA32271B1 (fr) | Composes inhibiteurs de kinases raf et procedes d'utilisation | |
CR20210189A (es) | Inhibidores de la proteina tirosina fosfatasa | |
MX2021012122A (es) | Inhibidores de la proteina tirosina fosfatasa. | |
WO2006125101A3 (fr) | Composes inhibiteurs raf et procedes d'utilisation de ceux-ci | |
TNSN07071A1 (fr) | Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases | |
ZA201003046B (en) | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-flammatory agents | |
MY148479A (en) | Piperidinyl-substituted isoquinolone derivatives | |
TNSN07070A1 (fr) | Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases | |
MY146644A (en) | Cyclohexylamin isoquinolone derivatives | |
MA28583B1 (fr) | Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
MA30900B1 (fr) | Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3 | |
MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
WO2007027855A3 (fr) | Composes inhibiteurs de la raf kinase et procedes d'utilisation de ceux-ci | |
NZ598985A (en) | Bruton's tyrosine kinase inhibitors | |
NO20091198L (no) | Azabenzotiofenylforbindelser og anvendelser derav | |
UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
WO2006105516A3 (fr) | Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques | |
MX2007011859A (es) | Compuestos mejorados farmacocineticamente. | |
MX2010002674A (es) | Moduladores de gamma secretasa. | |
MA32134B1 (fr) | Composés hétérocycliques | |
EA200600048A1 (ru) | Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
MA33839B1 (fr) | Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs | |
MA31167B1 (fr) | Inhibiteurs de l'activite de akt |